RBC Capital analyst Luca Issi maintained a Hold rating on Beam Therapeutics (BEAM – Research Report) on May 9 and set a price target of $85.00. The company’s shares closed last Tuesday at $35.78, close to its 52-week low of $32.90.
According to TipRanks.com, Issi is ranked 0 out of 5 stars with an average return of -35.8% and a 7.7% success rate. Issi covers the Healthcare sector, focusing on stocks such as Adverum Biotechnologies, BioMarin Pharmaceutical, and Crispr Therapeutics AG.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Beam Therapeutics with a $92.17 average price target, which is a 156.5% upside from current levels. In a report issued on May 9, J.P. Morgan also maintained a Hold rating on the stock with a $102.00 price target.
See the top stocks recommended by analysts >>
Beam Therapeutics’ market cap is currently $2.34B and has a P/E ratio of -5.60.
Based on the recent corporate insider activity of 38 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of BEAM in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Beam Therapeutics, Inc. develops and commercializes DNA base editing technologies for the treatment of human disease. Its licensed technology platform, which includes access to base editing technologies and associated technologies that enhance the scope of base editing. The company was founded by David R. Liu, Feng Zhang and J. Keith Joung on January 25, 2017 and is headquartered in Cambridge, MA.
Read More on BEAM:
- RBC Capital Keeps a Hold Rating on IGM Biosciences (IGMS)
- RBC Capital Maintains a Buy Rating on Osisko Development (RNGTD)
- RBC Capital Thinks Owl Rock Capital’s Stock is Going to Recover
- Verrica Pharmaceuticals (VRCA) Gets a Buy Rating from RBC Capital
- Crew Energy (CWEGF) Receives a Hold from RBC Capital
